Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
by on Wednesday, June 15th, 2011 | No Comments
Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival. Longer follow-up is needed to confirm the trends, but, if upheld, the results of these trials would support the first use of a biologic agent to treat ovarian cancer. Data from both trials were presented last week at the ASCO annual meeting in Chicago.
See the original post: Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients